Month: January 2018

Pradaxa vs Xarelto: Comparing Blood Thinners

Until the last decade, the only option available for patients with nonvalvular atrial fibrillation to help control blood clots was Coumadin (also known as warfarin). While effective in preventing intracranial bleeding, patients on Coumadin have to endure regular blood tests and risk major bleeding complications. Now there are new drugs known as non-vitamin K antagonist oral anticoagulants (NOACs).

The two anticoagulants at the forefront of the blood thinner market are Pradaxa (dabigatran), made by Boehringer Ingelheim, and Xarelto (rivaroxaban), manufactured by Johnson & Johnson’s Janssen Pharmaceuticals division. Both of these blood thinners are considered by some doctors to be safer and more effective than Coumadin. But they still come with increased risk of severe bleeding that have resulted in patients filing both Xarelto lawsuits and Pradaxa lawsuits by the thousands. Additionally, they are more expensive and may impact the renal system with prolonged use.

Because of these issues, we decided to do a head-to-head comparison between the two biggest rivals in this class of new blood thinners. Patients trying to choose the right blood thinner should consider the following things when weighing their options.

Judge tosses $27.8M Xarelto verdict

A Pennsylvania judge on Tuesday overturned a $27.8 million verdict against the makers of the blood thinner Xarelto in a lawsuit by an Indiana woman who claimed the drug caused severe gastrointestinal bleeding.

Judge Michael Erdos issued a judgment notwithstanding the verdict because of testimony by the prescribing doctor for plaintiff Lynn Hartman.

Erdos rejected an alternate ground for overturning the verdict that was based on an Instagram photo by a lawyer for the plaintiff that used the hashtag #killinnazis. Erdos nonetheless scolded and punished the lawyer for the post.

Still have questions?

Call (877) 932-2628 and speak with one of our legal funding experts.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in plaintiffs’ legal claims. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408